Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Kiladjian, Jean-Jacques  [Clear All Filters]
Journal Article
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti A-M, Sebert M, Boissel N, Robin M, Vey N, Kiladjian J-J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
Kiladjian J-J. Current Therapies and Their Indications for the Philadelphia-Negative Myeloproliferative Neoplasms. Am Soc Clin Oncol Educ Book. 2015;35:e389-e396.
Guadall A, Lesteven E, Letort G, Toor SAwan, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, et al. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thromb Haemost. 2018.
Godfrey AL, Campbell PJ, Maclean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol. 2018:JCO2018788414.
Mosca M, Hermange G, Tisserand A, Noble RJohn, Marzac C, Marty C, Le Sueur C, Campario H, Vertenoeil G, El-Khoury M, et al. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021.
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro C, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.
Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J-J, Griesshammer M, Mesa R, Ianotto JChristophe, Palandri F, Hernández-Boluda JCarlos, Birgegård G, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.